[Patient-Centered Outcomes Research Institute](https://www.pcori.org)

September 23, 2025 (LOI) | January 13, 2026 (Full application)

Up to $10 million total direct costs per project; maximum project period is 5 years.

Supports innovative, patient-centered comparative clinical effectiveness research on rare diseases, emphasizing strong patient and stakeholder engagement to generate actionable evidence for care and decision-making.

--- ## Description This funding opportunity supports high-quality, patient-centered comparative clinical effectiveness research (CER) focused on rare diseases. The program aims to address the unique scientific and clinical challenges in rare disease research by encouraging innovative approaches that prioritize patient and stakeholder perspectives throughout all phases of the research process. Multidisciplinary collaboration among health researchers, scientists, clinicians, and academic institutions is encouraged to generate robust, actionable evidence that can improve care and inform decision-making for rare disease populations. Projects should address significant evidence gaps and produce findings that are meaningful and relevant to patients, clinicians, and healthcare decision-makers. --- ## Due Dates - September 23, 2025: Letter of Intent (LOI) deadline (5 pm ET) - January 13, 2026: Full application deadline (5 pm ET) --- ## Funding Amount - Maximum total direct costs: Up to $10 million per project - Maximum project duration: 5 years --- ## Eligibility - Open to U.S.-based research organizations, including: - Academic institutions - Hospitals and health systems - Nonprofit and for-profit organizations - Patient and stakeholder organizations - Principal Investigators (PIs) must demonstrate experience relevant to CER and the proposed research topic. - Multidisciplinary teams and collaborations are encouraged. - Projects must feature comprehensive patient and stakeholder engagement throughout the research lifecycle. --- ## Application Process - Submit a Letter of Intent (LOI) by the published deadline. - Only invited applicants may submit a full application. - Applications must address all programmatic and administrative requirements, including detailed engagement plans. - Review the [PCORI funding announcement and applicant resources](https://www.pcori.org/funding-opportunities/announcement/addressing-rare-diseases-pcori-funding-announcement-cycle-3-2025) for templates and guidance. - Applicants are encouraged to contact PCORI program officers at [pfa@pcori.org](mailto:pfa@pcori.org) to discuss proposals prior to submission. --- ## Additional Information - Strong emphasis on patient-centeredness and engagement of relevant stakeholders. - Projects should fill significant evidence gaps in rare diseases and have the potential for broad impact. - LOI feedback will be provided prior to full application invitation. --- ## External Links - [PCORI Funding Announcement and Details](https://www.pcori.org/funding-opportunities/announcement/addressing-rare-diseases-pcori-funding-announcement-cycle-3-2025) - [PCORI Applicant Town Hall Presentation Slides](https://www.pcori.org/sites/default/files/PCORI-Cycle-3-2025-Rare-Disease-Applicant-Town-Hall-Presentation-Slides-081925.pdf) - [PCORI Funding Opportunities Overview](https://www.pcori.org/funding-opportunities) - [Contact PCORI](https://www.pcori.org/about/contact-us) --- ## Contact Information | Type | Details | |---------------------|----------------------------------------------| | General Inquiries | [info@pcori.org](mailto:info@pcori.org) | | Program Questions | [pfa@pcori.org](mailto:pfa@pcori.org) | | Phone | (202) 827-7700 | | Address | 1333 New Hampshire Avenue NW, Suite 1200, Washington, DC 20036 |

Cycle 3 2025 Addressing Rare Diseases PFA

Sign in to see full grant listing